1. Home
  2. PSTL vs DSGN Comparison

PSTL vs DSGN Comparison

Compare PSTL & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Postal Realty Trust Inc.

PSTL

Postal Realty Trust Inc.

HOLD

Current Price

$19.67

Market Cap

554.6M

Sector

Real Estate

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$12.67

Market Cap

579.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSTL
DSGN
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
554.6M
579.9M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
PSTL
DSGN
Price
$19.67
$12.67
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$19.25
$15.25
AVG Volume (30 Days)
205.9K
311.3K
Earning Date
04-29-2026
05-06-2026
Dividend Yield
5.11%
N/A
EPS Growth
123.81
N/A
EPS
0.47
N/A
Revenue
$95,823,000.00
N/A
Revenue This Year
$18.01
N/A
Revenue Next Year
$11.38
N/A
P/E Ratio
$40.85
N/A
Revenue Growth
25.47
N/A
52 Week Low
$12.26
$2.62
52 Week High
$21.13
$12.75

Technical Indicators

Market Signals
Indicator
PSTL
DSGN
Relative Strength Index (RSI) 60.46 71.49
Support Level $18.24 $9.71
Resistance Level $19.89 N/A
Average True Range (ATR) 0.46 0.57
MACD 0.09 0.23
Stochastic Oscillator 96.91 92.86

Price Performance

Historical Comparison
PSTL
DSGN

About PSTL Postal Realty Trust Inc.

Postal Realty Trust Inc is an internally managed real estate investment trust. It is engaged in acquiring and managing properties mainly leased to the United States Postal Service, or the USPS, ranging from last-mile post offices to industrial facilities. The Trust's objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of its revenue is generated in the form of rental income.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: